Alexion’s new U.S. head is looking for ‘the next generation of medicines to unpack’

A little more than a year since its acquisition by AstraZeneca plc, Alexion Pharmaceuticals Inc. is operating in "the best of both worlds" as the official rare disease unit of the U.K. pharma giant.